GlassScriptPhysician profile
Samantha Montealegre
NPI 1073052924
$1,823.57
in general payments reported to CMS, 2019-2025
19 companies · $738 in 2025
The $738 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15.16 · 2023: $555 · 2024: $515 · 2025: $738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,808.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $362.83 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $243.28 | 2023-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $227.14 | 2023-2025 | Spravato |
| Corium, LLC | $185.50 | 2023-2025 | Azstarys |
| Biogen, INC. | $157.90 | 2025 | Zurzuvae |
| Tris Pharma INC | $85.73 | 2024-2025 | Dyanavel Xr |
| Alkermes, INC. | $79.98 | 2023-2025 | Lybalvi |
| Supernus Pharmaceuticals, INC. | $76.21 | 2023 | Qelbree |
| Almatica Pharma LLC | $70.52 | 2023-2024 | Loreev Xr |
| Lundbeck LLC | $70.49 | 2024-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $58.28 | 2022-2024 | Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.05 | 2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $31.32 | 2024 | Quviviq |
| Ironshore Pharmaceuticals INC. | $27.23 | 2024 | |
| Vanda Pharmaceuticals INC. | $27.21 | 2025 | Fanapt |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $21.20 | 2023 | Ingrezza |
| Collegium Pharmaceutical, INC. | $19.61 | 2025 | Jornay Pm |
| Axsome Therapeutics, INC. | $19.11 | 2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $18.98 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Montealegre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.